Corrigendum to “Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model” [International Journal of Pharmaceutics 549 (2018) 218–229]

Shamili, Fazileh Hosseini; Bayegi, Houshang Rafatpanah; Salmasi, Zahra; Sadri, Kayvan; Mahmoudi, Mahmoud; Kalantari, Mahmoud Reza; Ramezani, Mohammad; Abnous, Khalil

doi:10.1016/j.ijpharm.2019.02.003

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extracellular vesicles (EVs) including exosomes and microvesicles are emerging innovative nano-sized drug delivery system (DDS) for cancer therapy [31]. EVs can be an ideal delivery vehicle for cancer therapeutic agents thanks to their many unique merits such as biological barrier penetration ability, tumor homing and organotropism, good bioavailability [10], innate stability and multi-drug loading capacity, little toxicity and immunogenicity [32]. Increasing evidences have demonstrated the great potential of EVs for delivery of therapeutic proteins and siRNAs for cancer treatment.…”

Section: Membranous Trail Carried By Evs Is Highly Efficient For Cancer Cell Killingmentioning

confidence: 99%

“…The safety of EV administration has been demonstrated by several phase I clinical studies with no grade II toxicity or maximal tolerated dose being found [8]. As an ideal drug delivery system, EVs can deliver not only soluble cargoes like microRNAs and mRNAs [9] but also membrane bound therapeutic molecules such as proteins and lipids [10].…”

Section: Introductionmentioning

confidence: 99%

“…It has been well demonstrated that TRAIL can be secreted via EVs by different types of cells that express TRAIL [10,11]. Importantly EV-carried TRAIL molecules (EV-T) may exist as membrane-bound oligomers, which are of higher efficiency for apoptosis induction.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

Chen

Hou

et al. 2020

Cancers

View full text Add to dashboard Cite

Tumour necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a promising anti-cancer agent that rapidly induces apoptosis in cancer cells. Unfortunately, the clinical application of recombinant TRAIL (rTRAIL) has been hampered by its common cancer resistance. Naturally TRAIL is delivered as a membrane-bound form by extracellular vesicles (EV-T) and is highly efficient for apoptosis induction. SCH727965 (dinaciclib), a potent cyclin-dependent kinase (CDK) inhibitor, was shown to synergize with other drugs to get better efficacy. However, it has never been investigated if dinaciclib coordinates with EV-T to enhance therapeutic results. This study explores the potential of combination therapy with EV-T and dinaciclib for cancer treatment. EV-T was successfully derived from human TRAIL transduced cells and shown to partially overcome resistance of A549 cells. Dinaciclib was shown to drastically enhance EV-T killing effects on cancer lines that express good levels of death receptor (DR) 5, which are associated with suppression of CDK1, CDK9 and anti-apoptotic proteins. Combination therapy with low doses of EV-T and dinaciclib induced strikingly enhanced apoptosis and led to complete regression in A549 tumors without any adverse side effects observed in a subcutaneous xenograft model. Tumor infiltration of mass NK cells and macrophages was also observed. These observations thus indicate that the combination of EV-T with dinaciclib is a potential novel therapy for highly effective and safe cancer treatment.

show abstract

Section: Membranous Trail Carried By Evs Is Highly Efficient For Cancer Cell Killingmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

Chen

Hou

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Exosomes secreted from MSCs are promising biological tools for targeted therapy in cancer. In this context, the injection of exosomes armed with TRAIL (Exo-TRAIL) secreted from MSCs reduced the tumor volume in tumor-bearing mice [ 206 ]. In a separate study using TRAIL resistant MCF-7 ER+ breast cancer cells, cell death was significantly increased when treated with ASCs overexpressing SMAC and TRAIL [ 207 ].…”

Section: Strategies To Improve Dr Agonists In Patients With Breast Ca...mentioning

confidence: 99%

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

Kundu

Greer

Dine

et al. 2022

Cells

View full text Add to dashboard Cite

The tumor necrosis factor (TNF) superfamily member TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in cancer cells via death receptor (DR) activation with little toxicity to normal cells or tissues. The selectivity for activating apoptosis in cancer cells confers an ideal therapeutic characteristic to TRAIL, which has led to the development and clinical testing of many DR agonists. However, TRAIL/DR targeting therapies have been widely ineffective in clinical trials of various malignancies for reasons that remain poorly understood. Triple negative breast cancer (TNBC) has the worst prognosis among breast cancers. Targeting the TRAIL DR pathway has shown notable efficacy in a subset of TNBC in preclinical models but again has not shown appreciable activity in clinical trials. In this review, we will discuss the signaling components and mechanisms governing TRAIL pathway activation and clinical trial findings discussed with a focus on TNBC. Challenges and potential solutions for using DR agonists in the clinic are also discussed, including consideration of the pharmacokinetic and pharmacodynamic properties of DR agonists, patient selection by predictive biomarkers, and potential combination therapies. Moreover, recent findings on the impact of TRAIL treatment on the immune response, as well as novel strategies to address those challenges, are discussed.

show abstract

Smart exosomes enhance PDAC targeted therapy

Creeden,

Sevier,

Zhang

et al. 2024

Journal of Controlled Release

View full text Add to dashboard Cite

Corrigendum to “Exosomes derived from TRAIL-engineered mesenchymal stem cells with effective anti-tumor activity in a mouse melanoma model” [International Journal of Pharmaceutics 549 (2018) 218–229]

Cited by 4 publications

References 0 publications

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy

Smart exosomes enhance PDAC targeted therapy

Contact Info

Product

Resources

About